Darabuş Diana-Maria, Munteanu Mihnea, Preda Maria-Alexandra, Karancsi Olimpiu Ladislau, Șuță Marius Cristian
Department of Ophthalmology, "Victor Babeş" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Department of Oral Implantology and Prosthetic Restorations on Implants, "Victor Babes" University of Medicine and Pharmacy, 300041 Timișoara, Romania.
Healthcare (Basel). 2023 May 12;11(10):1414. doi: 10.3390/healthcare11101414.
Branch retinal vein occlusions are a significant cause of vision loss and present several ophthalmic and systemic risk factors, including age, hypertension, hyperlipidemia and glaucoma. Retinal vein occlusion is the second-most-common retinal vascular disease. This study evaluated the effects of Ozurdex in contrast to a combination therapy with anti-vascular endothelial growth factor (VEGF) and cortisone in treatment-naive branch retinal vein occlusions-macular edema (BRVO-ME) cases, at 4-month and 6-month follow-ups. Thirty eyes were included in the study, which were divided into two groups. The first group consisted of 15 eyes, and each received 1 injection of dexamethasone intravitreal implant Ozurdex (DEX). The second group of 15 eyes received 3 intravitreal injections, the first and second with the anti-vascular endothelial growth factor aflibercept and the third one with 4 mg of triamcinolone acetonide (Vitreal S), spaced at one month. The best corrected visual acuity (BCVA) results suggested that the peak efficacy was at 4 months for both groups, with mean values of 0.5 LogMAR and 0.4 LogMAR. Regarding macular edema, there were no significant changes between the 4- and 6-month follow-up periods, with mean values of 361 μm and 390 μm. Six patients experienced transient raised intraocular pressure at one week after treatment. This study highlights the benefits to visual acuity of the combination of anti-vascular endothelial growth factor and cortisone, which represents a viable solution with similar results to Ozurdex therapy.
视网膜分支静脉阻塞是视力丧失的一个重要原因，存在多种眼科和全身危险因素，包括年龄、高血压、高脂血症和青光眼。视网膜静脉阻塞是第二常见的视网膜血管疾病。本研究评估了Ozurdex与抗血管内皮生长因子（VEGF）和可的松联合治疗初治的视网膜分支静脉阻塞性黄斑水肿（BRVO-ME）病例在4个月和6个月随访时的效果。该研究纳入了30只眼睛，分为两组。第一组有15只眼睛，每只眼睛接受1次玻璃体内注射地塞米松植入物Ozurdex（DEX）。第二组15只眼睛接受3次玻璃体内注射，第一次和第二次注射抗血管内皮生长因子阿柏西普，第三次注射4mg曲安奈德（Vitreal S），间隔1个月。最佳矫正视力（BCVA）结果表明，两组的疗效峰值均在4个月时出现，平均值分别为0.5 LogMAR和0.4 LogMAR。关于黄斑水肿，在4个月和6个月的随访期之间没有显著变化，平均值分别为361μm和390μm。6名患者在治疗后1周出现短暂性眼压升高。本研究强调了抗血管内皮生长因子和可的松联合治疗对视力的益处，这是一种与Ozurdex疗法效果相似的可行解决方案。
